Durable radiologic and clinical disease stability beyond PSA progression in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA)

被引：0
|
作者：
Bianchini, Diletta
Sandhu, Shahneen Kaur
Cassidy, Amy Mulick
Zivi, Andrea
Mezynski, Janusz
Mukherji, Deborah
Pezaro, Carmel Jo
Reid, Alison Helen
Oommen, Nikhil Babu
Olmos, David
Omlin, Aurelius Gabriel
Sarvadikar, Ajit
Thompson, Emilda
Hunt, Joanne
Sheridan, Elizabeth
Attard, Gerhardt
De Bono, Johann Sebastian
机构：
[1] Royal Marsden Hosp, Sutton, Surrey, England
[2] Inst Canc Res, Sutton, Surrey, England
[3] Royal Marsden Fdn Trust, Sutton, Surrey, England
[4] Royal Marsden Hosp, Dublin, Ireland
[5] Royal Marsden NHS Fdn Trust, London, England
[6] Inst Canc Res, London SW3 6JB, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4553
引用
收藏
页数：1
相关论文
共 50 条
  • [41] The effects of enzalutamide (ENZA) in combination with abiraterone acetate (AA) in patients with bone metastatic castration resistant prostate cancer (mCRPC)
    Efstathiou, E.
    Titus, M.
    Wen, A. S.
    San Miguel, A.
    Hoang, A.
    De Haas-Amatsaleh, A.
    Perabo, F.
    Phung, D.
    Troncoso, P.
    Logothetis, C.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S680 - S681
  • [42] Clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (ABI) stratified by prognosis
    Aviles, C. M.
    Azad, A. A.
    Todenhoefer, T.
    Eigl, B. J.
    Kollmannsberger, C.
    Murray, N.
    Chi, K.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S486 - S487
  • [43] Medication patterns of abiraterone acetate plus prednisone or enzalutamide and PSA progression in veterans with metastatic castration-resistant prostate cancer
    Freedland, Stephen J.
    Li, Sophia
    Pilon, Dominic
    Bhak, Rachel H.
    Narkhede, Sahil
    Lefebvre, Patrick
    Young-Xu, Yinong
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (04) : 635 - 642
  • [44] ARN-509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without prior abiraterone acetate (AA) treatment.
    Rathkopf, Dana E.
    Antonarakis, Emmanuel S.
    Shore, Neal D.
    Tutrone, Ronald F.
    Alumkal, Joshi J.
    Ryan, Charles J.
    Saleh, Mansoor N.
    Hauke, Ralph J.
    Bandekar, Rajesh
    Maneval, Edna Chow
    De Boer, Carla
    Todd, Mary Beth
    Yu, Margaret K.
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [45] Impact of prior response to abiraterone acetate (AA) on subsequent activity of docetaxel (D) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).
    Azad, Arun
    Lester, Renee
    Heng, Daniel Yick Chin
    Eigl, Bernhard J.
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [46] The Pacific trial: A randomized phase II study of OGX-427 in men with metastatic castration-resistant prostate cancer (mCRPC) and PSA progression while receiving abiraterone acetate (AA).
    Chi, Kim N.
    Sweeney, Christopher
    Jacobs, Cindy
    Stewart, Patricia S.
    Hahn, Noah M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [47] Abiraterone acetate plus prednisolone treatment beyond prostate specific antigen and radiographic progression in metastatic castration-resistant prostate cancer patients
    Biro, Krisztina
    Budai, Barna
    Szonyi, Marta
    Kuronya, Zsofia
    Gyergyay, Fruzsina
    Nagyivanyi, Krisztian
    Geczi, Lajos
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2018, 36 (02) : 81.e1 - 81.e7
  • [48] A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel.
    Chi, Kim N.
    San Kheoh, Thian
    Ryan, Charles J.
    Molina, Arturo
    Bellmunt, Joaquim
    Vogelzang, Nicholas J.
    Rathkopf, Dana E.
    Fizazi, Karim
    Kantoff, Philip W.
    Li, Jinhui
    De Bono, Johann Sebastian
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [49] A prognostic score for patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate post chemotherapy
    Templeton, Arnoud J.
    Omlin, Aurelius Gabriel
    Pezaro, Carmel Jo
    Kheoh, Thian San
    Leibowitz-Amit, Raya
    Vera-Badillo, Francisco Emilio
    Tannock, Ian
    Attard, Gerhardt
    Amir, Eitan
    De Bono, Johann Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [50] Evaluation of PSA progression after initiation of enzalutamide or abiraterone: Real-world data on metastatic castration-resistant prostate cancer (mCRPC).
    Lopez-Campos, Fernando
    Lorente, David
    Llacer Perez, Casilda
    Ramirez-Backhaus, Miguel
    Peleteiro, Paula
    Gomez-Iturriaga, Alfonso
    Henriquez-Lopez, Ivan
    Lozano, Rebeca
    Romero, Nuria
    Alonso-Gordoa, Teresa
    Molina-Cerrillo, Javier
    Navarro-Castellon, Joaquin
    Castano, Ana
    Pelari, Lira
    Hernandez-Corrales, Antonio
    Morillo, Virginia
    Garcia, Raquel
    Ferrer Albiach, Carlos
    Castro, Elena
    Olmos, David
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345